|
Market Closed -
Australian S.E.
00:10:12 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 7.420 AUD | -2.88% |
|
-1.33% | -40.45% |
| 11-06 | Clinuvel Pharmaceuticals Limited - Shareholder/Analyst Call | |
| 10-30 | Clinuvel Pharmaceuticals Ltd Files Neuracthel Instant Dossier | CI |
| Market Cap | 374M 254M 230M 213M 192M 361M 23.91B 2.55B 1.01B 12.77B 952M 932M 40.55B | P/E 2027 * |
10.8x | P/E 2028 * | 10.4x |
|---|---|---|---|---|---|
| Enterprise Value | 91.07M 61.72M 55.93M 51.73M 46.68M 87.96M 5.82B 621M 246M 3.11B 232M 227M 9.87B | EV / Sales 2027 * |
0.96x | EV / Sales 2028 * | 0.58x |
| Free-Float |
83.52% | Yield 2027 * |
0.74% | Yield 2028 * | 0.8% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CUV | Delayed | |
Tradegate
| UR9 | Real-time | |
|
Boerse Muenchen
| UR9 | Real-time | |
|
OTC Markets
| CLVLF | Delayed | |
|
Deutsche Boerse AG
| UR9 | Delayed | |
|
Börse Stuttgart
| UR9 | Delayed |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -2.88% | ||
| 1 week | -1.33% | ||
| Current month | +2.77% | ||
| 1 month | -2.50% | ||
| 3 months | -22.30% | ||
| 6 months | -22.22% | ||
| Current year | -40.45% |
| 1 week | 7.32 |  | 7.76 |
| 1 month | 6.62 | | 8.3 |
| Current year | 6.62 | | 13.48 |
| 1 year | 6.62 | | 13.48 |
| 3 years | 6.62 | | 18.2 |
| 5 years | 6.62 | | 33.51 |
| 10 years | 5.91 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/3/24 | Buy | Director | 8,333 | 0.0166% | ||
| 11/27/23 | Exercice | Chief Executive Officer | 301,125 | 0.6094% | ||
| 11/27/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.88% | -1.33% | -33.03% | -53.62% | 254M | |
| +1.26% | +6.61% | +40.79% | +136.32% | 1,286B | |
| +0.79% | +3.45% | +45.84% | +93.52% | 688B | |
| +0.20% | +1.28% | +26.97% | +113.70% | 521B | |
| -0.44% | +3.69% | +41.45% | +68.91% | 386B | |
| +0.55% | +0.70% | +59.02% | +44.62% | 364B | |
| -0.12% | +0.74% | +28.39% | +58.54% | 302B | |
| +0.37% | +0.37% | +3.33% | +37.27% | 287B | |
| -0.30% | +1.14% | +38.29% | +72.46% | 252B | |
| +0.08% | +0.71% | +34.44% | +124.95% | 208B | |
| Average | -0.05% | +1.74% | +28.55% | +69.66% | 429B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.69% | +96.49% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.47M 64.03M 58.02M 53.67M 48.42M 91.25M 6.04B 645M 256M 3.23B 240M 235M 10.24B | 100M 68.03M 61.65M 57.02M 51.45M 96.96M 6.41B 685M 272M 3.43B 255M 250M 10.88B |
| Net income | 34.94M 23.68M 21.46M 19.85M 17.91M 33.75M 2.23B 238M 94.55M 1.19B 88.87M 86.99M 3.79B | 36.32M 24.62M 22.31M 20.63M 18.62M 35.08M 2.32B 248M 98.28M 1.24B 92.38M 90.42M 3.94B |
| Net Debt | -283M -192M -174M -161M -145M -273M -18.09B -1.93B -766M -9.66B -720M -705M -30.68B | -316M -214M -194M -179M -162M -305M -20.17B -2.15B -854M -10.77B -803M -786M -34.2B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-13 | A$7.420 | -2.88% | 78,788 |
| 26-11-12 | A$7.640 | +1.19% | 148,675 |
| 26-11-11 | A$7.550 | +1.75% | 204,169 |
| 26-11-10 | A$7.420 | -1.98% | 71,201 |
| 26-11-09 | A$7.570 | +0.66% | 95,700 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
